Patents Examined by Olga V Tcherkasskaya
  • Patent number: 12012424
    Abstract: A process is provided for the production of bis-choline tetrathiomolybdate, the process comprising reacting a choline salt with ammonium tetrathiomolybdate, wherein the choline salt is a hydroxide, acetate, or halide choline salt, wherein the process comprises: combining the choline salt with a first mixture of ammonium tetrathiomolybdate in water, wherein a molar excess of choline salt to ammonium tetrathiomolybdate is used, for a first reaction period to provide a first reaction mixture; subjecting the first reaction mixture to a reduced pressure for a second reaction period to provide a second reaction mixture; and, isolating bis-choline tetrathiomolybdate from the second reaction mixture, wherein isolating bis-choline tetrathiomolybdate comprises adding ethanol to the second reaction mixture.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 18, 2024
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Johan Anders Wennerberg, Hans Roger Marcus Mårtensson
  • Patent number: 12005037
    Abstract: The present invention relates to bioavailable fill compositions containing one or more of a decongestant, an expectorant, an antitussive, an analgesic, and/or an antihistamine; capsules filled with the bioavailable fill compositions; and methods of making same.
    Type: Grant
    Filed: September 19, 2022
    Date of Patent: June 11, 2024
    Inventors: Minh Tran, Yi Zeng, Zhang Julia Zhang, Hengsheng Feng, Dahai Guo
  • Patent number: 12005140
    Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as adrenaline, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of a condition selected from anaphylaxis, superficial bleeding and cardiac arrest.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 11, 2024
    Assignee: Klaria Pharma Holding AB
    Inventors: Scott Boyer, Shengzhen Cai, Fredrik Hübinette, Leif Ingemarsson
  • Patent number: 11986509
    Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer. The kappa opioid receptor agonist may be coated with, embedded in or mixed with an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists, the oligosaccharide and the absorption enhancer of the invention. The invention further provides methods of manufacture of the formulations and methods of their use for the prophylaxis, inhibition and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation. The methods of use include administering to the mammal the formulation of the kappa opioid receptor agonist, oligosaccharide and optional absorption enhancers.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: May 21, 2024
    Assignee: Cara Therapeutics, Inc.
    Inventors: Bryan R. Wilson, Stephen J. O'Connor
  • Patent number: 11980692
    Abstract: A process prepares a polymer-coated hard shell capsule, suitable as container for pharmaceutical or nutraceutical biologically active ingredients. The hard shell capsule can include a body and a cap. In the closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule can be provided in the pre-locked state and spray-coated with a coating solution, suspension, or dispersion that includes a polymer or a mixture of polymers to create a coating layer which covers the outer surface of the hard shell capsule in the pre-locked state.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: May 14, 2024
    Assignee: Evonik Operations GmbH
    Inventors: Ashish Guha, Vishal Kaneria, Vinay Jain, Shraddha Joshi, Miriam Robota, Felix Hofmann, Marcel Arndt, Hans Bär
  • Patent number: 11980691
    Abstract: Enteric softgel capsules comprise a fill material and an enteric shell composition, characterized in that the enteric nature of the capsules may be achieved without an enteric coating or added conventional enteric polymers.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 14, 2024
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Toshikazu Okayama, Miyako Takahashi, Takuma Fujii
  • Patent number: 11976300
    Abstract: Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: May 7, 2024
    Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Haiyan Xu, Jian Liu, Tao Wang, Bing Han, Jie Meng, Tao Wen
  • Patent number: 11964054
    Abstract: Formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: Iterion Therapeutics, Inc.
    Inventors: Gowri Sukumar, Drazen Ostovic
  • Patent number: 11944597
    Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: April 2, 2024
    Assignee: XWPHARMA LTD.
    Inventors: Daniel M. Canafax, William W. Xiang, Leonard Blum, Jia-Ning Xiang
  • Patent number: 11938222
    Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 26, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Zhaolu Zhu, Yun Wu, Di Lu, Yanping Zhao, Liying Zhou, Yanan Liu
  • Patent number: 11931379
    Abstract: Compositions, systems and methods of dispensing compositions for treating skin conditions, the compositions including an inorganic compound and having desirable viscosity, spreadability and foam drainage profiles.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 19, 2024
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Jiger Patel
  • Patent number: 11925710
    Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: March 12, 2024
    Assignee: XWPHARMA LTD.
    Inventors: Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Stefanie Thiel, Norbert Pollinger, Annette Grave
  • Patent number: 11918684
    Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 5, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
  • Patent number: 11918685
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: May 30, 2023
    Date of Patent: March 5, 2024
    Assignee: AZURITY PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Patent number: 11904006
    Abstract: A composition comprising particles formed of poly(diaminosulfide) and one or more leptospiral antigens, and methods of making and using the composition, are provided.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: February 20, 2024
    Assignees: University of Iowa Research Foundation, The United States of America, As Represented by The Secretary of Agriculture
    Inventors: Aliasger K. Salem, Emad I. Wafa, Sean M. Geary, Ned B. Bowden, Jennifer H. Wilson-Welder, David P. Alt
  • Patent number: 11896740
    Abstract: Compositions for forming porous materials and three-dimensional objects, including fibers, films and coatings made from the materials are provided. Also provided are methods for forming the porous objects from the compositions. The compositions include a solvent, a polymer binder that is soluble in the solvent, and solid particles that are insoluble in the solvent. The solid particles include water-soluble salt particles that can be selectively dissolved from objects made from the compositions to render the resulting structures porous.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 13, 2024
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Adam E. Jakus, Ramille N. Shah, Nicholas R. Geisendorfer
  • Patent number: 11896573
    Abstract: Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: February 13, 2024
    Assignee: XWPHARMA LTD.
    Inventors: William W. Xiang, Jia-Ning Xiang, Daniel M. Canafax
  • Patent number: 11890383
    Abstract: The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: February 6, 2024
    Assignee: Capsugel Belgium NV
    Inventors: Ljiljana Palangetic, Delphine Nombret, Stefaan Jaak Vanquickenborne
  • Patent number: 11883537
    Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: January 30, 2024
    Assignee: Axial Therapeutics, Inc.
    Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
  • Patent number: 11883467
    Abstract: An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: January 30, 2024
    Assignee: Elgan Pharma Ltd
    Inventors: Michal Olshansky, Elena Ostrovsky, Stav Zeldis